In recent years, immunotherapies, represented by programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1), have gradually become the foundational treatments for advanced lung cancer [36, 37], and significant clinical progress has been achieved in NSCLC [36]. Here, PDCD1 is linked to non-small cell lung carcinoma.